My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 424

    1.

    Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.

    Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, Hashimoto E, Hirota K, Yoshida H, Ohashi Y, Omata M; Tokyo-Chiba Hepatitis Research Group.

    Ann Intern Med. 2005 Jan 18;142(2):105-14.PMID: 15657158 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

    Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T.

    Int J Cancer. 2000 Sep 1;87(5):741-9.PMID: 10925370 [PubMed - indexed for MEDLINE]Related articles

    3.

    Summaries for patients. Long-term effects of antiviral treatment for hepatitis C.

    [No authors listed]

    Ann Intern Med. 2005 Jan 18;142(2):I51. No abstract available. PMID: 15657153 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.

    Ann Intern Med. 1999 Aug 3;131(3):174-81.PMID: 10428733 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL.

    Ann Intern Med. 2007 Nov 20;147(10):677-84.PMID: 18025443 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death.

    Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N.

    J Viral Hepat. 2004 Mar;11(2):148-56.PMID: 14996350 [PubMed - indexed for MEDLINE]Related articles

    7.

    Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.

    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.

    J Gastroenterol Hepatol. 2007 May;22(5):669-75.PMID: 17444854 [PubMed - indexed for MEDLINE]Related articles

    8.

    Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

    Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M.

    Ann Intern Med. 2003 Feb 18;138(4):299-306.PMID: 12585827 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.

    Floreani A, Baldo V, Rizzotto ER, Carderi I, Baldovin T, Minola E.

    J Clin Gastroenterol. 2008 Jul;42(6):734-7.PMID: 18285717 [PubMed - indexed for MEDLINE]Related articles

    10.

    Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

    Gramenzi A, Andreone P, Fiorino S, Cammà C, Giunta M, Magalotti D, Cursaro C, Calabrese C, Arienti V, Rossi C, Di Febo G, Zoli M, Craxì A, Gasbarrini G, Bernardi M.

    Gut. 2001 Jun;48(6):843-8.PMID: 11358906 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.

    Shindo M, Ken A, Okuno T.

    Cancer. 1999 May 1;85(9):1943-50.PMID: 10223234 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

    Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y.

    Ann Intern Med. 1998 Jul 15;129(2):94-9.PMID: 9669992 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.

    Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F, Icardi G, Valente U.

    Hepatogastroenterology. 2002 Nov-Dec;49(48):1636-8.PMID: 12397752 [PubMed - indexed for MEDLINE]Related articles

    14.

    Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.

    Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN.

    J Gastroenterol Hepatol. 2005 Oct;20(10):1553-9.PMID: 16174073 [PubMed - indexed for MEDLINE]Related articles

    15.

    A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.

    Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF.

    Antivir Ther. 2006;11(8):985-94.PMID: 17302368 [PubMed - indexed for MEDLINE]Related articles

    16.

    Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.

    Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Tanikawa M, Sone Y, Hisanaga Y, Hayashi K.

    Hepatogastroenterology. 2002 Nov-Dec;49(48):1619-24.PMID: 12397749 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.

    Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T.

    Oncology. 2001;61(2):134-42.PMID: 11528252 [PubMed - indexed for MEDLINE]Related articles

    18.

    Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

    Omata M, Yoshida H, Shiratori Y.

    Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3. Review.PMID: 16234063 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.

    Inoue A, Tsukuma H, Oshima A, Yabuuchi T, Nakao M, Matsunaga T, Kojima J, Tanaka S.

    J Epidemiol. 2000 Jul;10(4):234-40.PMID: 10959605 [PubMed - indexed for MEDLINE]Related articles

    20.

    Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.

    Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, Boucher E, Miguet JP, Parlier D, Lemonnier C, Opolon P.

    Hepatology. 1999 Jun;29(6):1870-5.PMID: 10347132 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity